Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer

Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer

Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches that have drastically changed the course of the disease. In particular due to the high sensitivity of prostate cancer cells to hormone depletion, several agents able to inhibit hormone production or bind...

Full description

Bibliographic Details
Main Authors:	Veronica Mollica, Vincenzo Di Nunno, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Matteo Santoni, Marina Scarpelli, Rodolfo Montironi, Francesco Massari
Format:	Article
Language:	English
Published:	MDPI AG 2019-01-01
Series:	Cells
Subjects:	hormone inhibition resistance prostate cancer (PCa), castration-resistance PCa AR splice variants epigenetic mechanisms
Online Access:	http://www.mdpi.com/2073-4409/8/1/43

Similar Items

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
by: Gaetano Aurilio, et al.
Published: (2020-12-01)

New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
by: Gaetano Aurilio, et al.
Published: (2020-06-01)

Galeterone for the treatment of advanced prostate cancer: the evidence to date
by: Bastos DA, et al.
Published: (2016-07-01)

Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
by: Marzieh Ehsani, et al.
Published: (2021-03-01)

Therapeutic Approaches to Targeting Androgen Receptor Splice Variants
by: Violet A. Daniels, et al.
Published: (2024-01-01)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
by: Balaji Chandrasekaran, et al.
Published: (2023-03-01)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
by: Anieta M. Sieuwerts, et al.
Published: (2019-08-01)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
by: Farhan Khan, et al.
Published: (2023-02-01)

Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
by: Rodolfo Montironi, et al.
Published: (2020-04-01)

Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic
by: Alessia Cimadamore, et al.
Published: (2021-05-01)

TR3 Enhances AR Variant Production and Transactivation, Promoting Androgen Independence of Prostate Cancer Cells
by: Tuyen Thanh Tran, et al.
Published: (2022-04-01)

AR Splicing Variants and Resistance to AR Targeting Agents
by: Mayuko Kanayama, et al.
Published: (2021-05-01)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
by: Luca Urso, et al.
Published: (2023-11-01)

The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer
by: Lei Tian, et al.
Published: (2022-11-01)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
by: Navid Sobhani, et al.
Published: (2021-05-01)

A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8<sup>+</sup> T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice
by: Pauline Le Vu, et al.
Published: (2022-04-01)

Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer
by: Fabrizio Fontana, et al.
Published: (2021-05-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Targeting Prostate Cancer, the ‘Tousled Way’
by: Siddhant Bhoir, et al.
Published: (2023-07-01)

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancerResearch in context
by: Chiu-Lien Hung, et al.
Published: (2023-04-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways
by: Yunlim Kim, et al.
Published: (2023-06-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation
by: Alessia Cimadamore, et al.
Published: (2021-07-01)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
by: Yan Li, et al.
Published: (2022-11-01)

Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells
by: Morais M, et al.
Published: (2022-09-01)

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
by: Veronica Mollica, et al.
Published: (2019-06-01)

Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man
by: Denise Chronscinski, et al.
Published: (2015-09-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)

The Human Microbiota and Prostate Cancer: Friend or Foe?
by: Francesco Massari, et al.
Published: (2019-03-01)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
by: Jun Luo
Published: (2016-01-01)

Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis
by: Gianpaolo Perletti, et al.
Published: (2015-07-01)

From Therapy Resistance to Targeted Therapies in Prostate Cancer
by: Filipa Moreira-Silva, et al.
Published: (2022-05-01)

A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
by: Peng Gu, et al.
Published: (2019-06-01)

Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network
by: Ahn R. Lee, et al.
Published: (2018-04-01)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
by: Fuqiang Ban, et al.
Published: (2021-07-01)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
by: Iris Simon, et al.
Published: (2021-03-01)

Prostate cancer small extracellular vesicles participate in androgen-independent transformation of prostate cancer by transferring let-7a-5p
by: Lin Lei, et al.
Published: (2022-12-01)

E74-like factor inhibition induces reacquisition of hormone sensitiveness decreasing period circadian protein homolog 1 expression in prostate cancer cells
by: Kohei Koyama, et al.
Published: (2015-03-01)